Literature DB >> 385602

Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

A S Douvas, M Achten, E M Tan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 385602

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  67 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 2.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

3.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Identification of protein components reactive with anti-PM/Scl autoantibodies.

Authors:  C Gelpi; A Algueró; M Angeles Martinez; S Vidal; C Juarez; J L Rodriguez-Sanchez
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

5.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 6.  Antinuclear autoantibodies: probes for defining proteolytic events associated with apoptosis.

Authors:  C A Casiano; E M Tan
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

7.  Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma.

Authors:  M Labrador; A Algueró; C Díaz; C Geli; E Pérez; J García-Valero; J L Rodriguez-Sanchez; C Gelpí
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

Authors:  Pravitt Gourh; Sandeep K Agarwal; Dipal Divecha; Shervin Assassi; Gene Paz; Rajpreet K Arora-Singh; John D Reveille; Sanjay Shete; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2009-12

Review 10.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.